{"id":28304,"date":"2023-07-21T10:10:41","date_gmt":"2023-07-21T09:10:41","guid":{"rendered":"https:\/\/cannabishealthnews.co.uk\/?p=28304"},"modified":"2023-07-21T10:10:44","modified_gmt":"2023-07-21T09:10:44","slug":"uk-company-identifies-potential-cannabinoid-based-cancer-treatment","status":"publish","type":"post","link":"https:\/\/cannabishealthnews.co.uk\/2023\/07\/21\/uk-company-identifies-potential-cannabinoid-based-cancer-treatment\/","title":{"rendered":"UK company identifies potential new cannabinoid-based cancer treatment"},"content":{"rendered":"

A UK pharmaceutical company producing prescription cannabinoid medicines, has announced its expansion into oncology with the development of a potential \u2018first in class\u2019 cancer treatment.\u00a0<\/strong><\/h3>\n

Oxford Cannabinoid Technologies Plc (OCTP), which has been developing cannabinoid-based medicines since 2017,\u00a0announced this week it is expanding its research and development to focus on a new drug with the potential to treat cancer.\u00a0<\/a><\/span><\/p>\n

The company has identified a potential \u2018first in class\u2019 immunotherapy agent which could be taken as a tablet to treat solid tumours as an <\/span>alternative to existing therapies.<\/span><\/p>\n

The new drug candidate was identified from OCTP\u2019s library of almost 500 cannabinoid derivatives after it signed an exclusive licence agreement with Canopy Growth Corporation.<\/span><\/p>\n

During an investor update on Wednesday 19 July, OCTP’s chief scientific officer, <\/span>Dr Valentino Parravicini, explained how following<\/span> analysis of the initial data, the team believes the molecule\u00a0<\/span>demonstrates \u2018significant potential\u2019 in both <\/span>in vitro [test tubes] and in vivo [living organism] studies.<\/span><\/p>\n

Immunotherapy treatment in cancer\u00a0<\/b><\/h4>\n

Immunotherapy is a form of treatment which uses the body\u2019s immune system to fight cancer. Existing <\/span>types of immunotherapy<\/span><\/a> include<\/span> monoclonal antibodies, checkpoint inhibitors, and vaccines, as well as targeted treatments or biological therapies.\u00a0<\/span><\/p>\n

They all work in different ways in order to help the immune system recognise and attack cancer cells <\/span>and then prevent or delay cancer reappearance.<\/span><\/p>\n

Immunotherapy is not always suitable for patients and is <\/span>currently only licensed to treat certain advanced cancers. As with many forms of cancer treatment it may also come with <\/span>side effects,<\/span><\/a> including fatigue and inflammatory<\/span> and autoimmune complications, which can affect any part of the body.\u00a0<\/span><\/p>\n

Dr Parravicini explained how the new compound works on a mechanism of action which removes the \u2018hand brake\u2019 which the cancer sets on the patient\u2019s immunity, triggering the patient\u2019s own immune cells to attack the cancer again.<\/span><\/p>\n

\u201c<\/span>Observations show that tumour growth is in some cases associated with increased levels of endocannabinoids, both at the tumour level and in the blood,” he said.<\/span><\/p>\n

“In this case, some of these endocannabinoids actually have a detrimental effect in immunotherapy against the tumour. <\/span>The tumour should be killed by the immune system, but it finds a way to bypass it. In that case, what we say is that the tumour microenvironment is \u2018cold\u2019 meaning that the tumour is not detected by the immune system. The immunosuppressive cells actually block the immune system, or put a handbrake on it, if you like, and the tumour grows and forms metastasis. “<\/span><\/p>\n

He continued: \u201cOur idea is to change that using our derivative to actually release this handbrake. We increase the inflammation so that the tumour microenvironment becomes hot, and the patient\u2019s own cytotoxic cells can actively kill it.\u201d<\/span><\/p>\n

A cheaper and more accessible treatment option?<\/h4>\n

Current treatments achieve this mechanism of action through antibodies or cell therapies, but these can be expensive and hard to access, usually requiring travel to specialist cancer centres.<\/span><\/p>\n

OCTP believes the new drug could be taken at home as a tablet, potentially making it cheaper for both public and private healthcare providers and more convenient for patients.<\/span><\/p>\n

Attention will now focus on further in vitro and in vivo studies, followed by a safety-pharmacology assessment with the final candidate selection likely to take place in 2024.\u00a0<\/span><\/p>\n

Clarissa Sowemimo-Coker, chief executive officer, commented: \u201cThere is an urgent need for new cancer medications. The OCTP team has discovered a potential first-line-treatment alternative to existing therapies and their side effects which could provide a viable alternative to expensive biologics. Although we\u2019re at an early stage, this is exciting news for the company.<\/span><\/p>\n

\u201cAs the potential of cannabinoid-based medicines to treat a range of conditions in a less harmful and more economic manner receives growing public recognition, OCTP stands at the forefront of research and development and we are extremely excited to have identified a possible candidate that could have a significant impact on many peoples\u2019 lives.<\/span><\/p>\n

Sowemimo-Coker added: \u201cWe are innovative specialists within the global pain and oncology markets and we will continue to develop new opportunities that will ultimately benefit people suffering with a range of debilitating, life altering conditions.\u201d<\/span><\/p>\n

Meeting unmet needs in neuropathic pain\u00a0<\/b><\/h4>\n

OCTP is already making significant progress with the development of new cannabinoid-based drugs to treat chemotherapy-induced peripheral neuropathy <\/span>(CIPN) and trigeminal neuralgia (TN).\u00a0<\/a><\/span><\/p>\n

The company has <\/span>received MHRA approval for the first in-human Phase 1 double-blind randomised control trial on its patented cannabinoid-based molecule, OCT461201 to treat CIPN, with the first dose expected to be administered in participants imminently.<\/span><\/p>\n

It has also completed safety and toxicology studies and on a metered-dose inhaler to administer a combination of synthetic cannabinoids, dronabinol (THC) and CBD in patients with TN.\u00a0<\/span><\/p>\n

TN is a hard-to-treat pain condition which causes bursts of sharp, excruciating nerve pain usually to one side of the face.<\/span><\/p>\n

\u201cThis is another area of very significant unmet medical need,” said OCTP’s chief medical officer, Dr Tim Corn.<\/span><\/p>\n

“There is only one drug approved for the treatment of trigeminal neuralgia but it’s an anticonvulsant and it has a life threatening side-effect.”<\/span><\/p>\n

He continued: “This is a very severe pain. It can be acute, it can become chronic, and it can become recurrent. A wide range of other drugs are used, including gabapentinoids antidepressants, Botox and even sometimes surgery to relieve this condition. The prospect of a treatment that can be delivered very quickly with an inhaler in the acute situation, and chronically for patients who have the condition, is really very exciting.\u201d<\/span><\/p>\n

Several clinical trials have shown the efficacy of combined THC\/CBD therapy in neuropathic pain.<\/a> The inhaler device is designed to deliver a consistent metered dose with better absorption and bioavailability for faster onset of pain relief.\u00a0<\/span><\/p>\n

OCTP is now beginning the process of applying for regulatory approval to conduct Phase 1 trials in Australia.<\/span><\/p>\n

Want more stories like this delivered directly to your inbox? Sign up for our free weekly newsletter here.\u00a0<\/a><\/em><\/h4>\n

\u00a0<\/p>\n\n\n